Newsroom

September 2016

• 
  Story Sep 22, 2016 Patient Perspectives

  Body painter captures anguish of those who suffer from psoriasis

  To understand the impact of psoriasis on those who live with it, we helped organize a global survey of more than 8,000 people who have this skin condition. Then we commissioned a body painter to bring the results to life, using skin as her canvas.

• Press release Sep 21, 2016

  Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs

  Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites…
• In The News Sep 20, 2016

  Novartis Access perspectives: Making Medicines Affordable for the World’s Poorest People

  An editorial by Anthony Gitau, Head of Novartis Access in Kenya
• Press release Sep 19, 2016

  Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients

  New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…
• Press release Sep 17, 2016

  Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients

  EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary…
• Press release Sep 16, 2016

  New Novartis data presented at ECTRIMS show benefit of Gilenya® on patient disability progression at 10 years

  ACROSS study shows that patients with relapsing remitting multiple sclerosis (RRMS) continuously treated with Gilenya® (fingolimod) had significantly lower disability progression compared to those…
• Press release Sep 15, 2016

  Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine

  Detailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine…
• 
  Story Sep 15, 2016 From Our Labs

  Three lessons I’ve learned as an industry postdoc

  An immunologist shares tips from a team-based environment

• Press release Sep 15, 2016

  Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress

  Emerging evidence from first 18 months of LPEP program demonstrates operational feasibility integrating single-dose rifampicin into routine control programs in 6 countries  Retrospective…
• 
  Story Sep 12, 2016 Discovery

  Reaping cancer clues from the blood

  NIBR investigator develops technology that uses tumor DNA in the blood for diagnostics

• Press release Sep 09, 2016

  New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions

  NijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions  Point of care in office…
• 
  Story Sep 08, 2016 Discovery

  A cellular drama at the heart of a researcher’s family

  Jennifer Allport-Anderson hunts for cardiac cures.